October 2026 English edition · Evidence reviewed through October 3, 2026 · David Shusterman, MD

Appendix L: The Procedure Decision Guide

No single stone procedure is best for every patient. Procedure selection is a matching exercise involving stone size, location, density, anatomy, infection status, kidney function, anticoagulation, pregnancy, prior procedures, patient preference, available technology, and the surgeon’s experience. The correct question is not “Which operation is newest?” It is “Which option gives this patient the best balance of clearance, safety, recovery, and future flexibility?”

Observation and Medical Expulsive Therapy

Observation avoids anesthesia and instrumentation and is appropriate for selected stable ureteral stones with a reasonable chance of spontaneous passage. The tradeoff is uncertainty. The patient must tolerate symptoms, maintain hydration and medication, remain free of infection, and complete follow-up. Medical expulsive therapy may be offered to selected patients, particularly for certain distal ureteral stones, but it is not a support and does not replace monitoring.

Observation becomes less attractive when the stone is larger, proximal, impacted, associated with worsening obstruction, causing recurrent emergency visits, or threatening work, travel, pregnancy, renal function, or reliable access to care. Patient preference matters. A stable patient may reasonably choose intervention after understanding both pathways.

Ureteroscopy

Ureteroscopy uses a small semirigid or flexible scope passed through the urethra and bladder into the ureter or kidney. A laser fragments the stone, and selected fragments may be removed with a basket. Modern ureteroscopy offers a high probability of treating many ureteral and renal stones in one anesthetic session.

Its advantages include direct visualization, the ability to treat stones resistant to shockwave fragmentation, and applicability across many locations. Its tradeoffs include anesthesia, temporary postoperative discomfort, possible ureteral swelling, infection risk, and the possibility of a stent. Rare complications include ureteral injury or later stricture. These risks should be described accurately without portraying them as inevitable.

A stent may be omitted after selected uncomplicated ureteroscopies when specific safety criteria are met. The decision depends on ureteral trauma, residual obstruction, infection, stone burden, renal function, anatomy, and surgeon judgment. Stent-free surgery is not a promise that should override safety.

Shockwave Lithotripsy

Shockwave lithotripsy focuses externally generated acoustic energy on a stone to break it into smaller fragments that can pass through the urinary tract. Its appeal is that no scope is advanced through the ureter. It is often performed with lighter anesthesia than ureteroscopy, although practice varies.

Success depends on patient and stone factors. Stone location, size, density on CT, body habitus, skin-to-stone distance, lower-pole anatomy, and stone composition can influence fragmentation and clearance. Some dense calcium oxalate monohydrate or cystine stones may fragment poorly. Lower-pole fragments may remain despite successful breakage because gravity and anatomy impede drainage.

The tradeoff is that fragmentation is not the same as clearance. Some patients require repeat treatment or a secondary ureteroscopy. Fragment passage can cause colic, and a larger fragment burden can obstruct the ureter. SWL is therefore a selective tool, not a universally gentle alternative and not an inherently harmful technology.

Percutaneous Nephrolithotomy and Mini-PCNL

PCNL creates a tract through the flank directly into the kidney, allowing larger instruments to fragment and remove substantial stone burdens. It is commonly favored for large, complex, or staghorn stones because it can achieve greater clearance than techniques that depend on passing many fragments through the ureter.

Standard PCNL offers working space and efficient removal but involves a renal access tract and a greater bleeding burden than ureteroscopy or SWL. Mini-PCNL uses a smaller tract and may reduce some morbidity while preserving strong clearance for selected stones. The exact terminology and tract sizes vary among centers.

Recovery depends on complexity, bleeding, infection risk, residual fragments, and whether a nephrostomy tube or stent is left. Some patients go home quickly; others require hospitalization. “Minimally invasive” does not mean trivial, but it also does not mean that major surgery should be feared when it is the most efficient way to protect a kidney from a large burden.

Urgent Drainage: Stent or Nephrostomy

When an obstructed collecting system is infected, when renal function is threatened, or when urgent decompression is otherwise required, the immediate goal may be drainage rather than stone removal. A ureteral stent bypasses the obstruction internally. A percutaneous nephrostomy tube drains the kidney through the back.

Both methods can be effective. The choice depends on patient stability, anatomy, stone location, availability, anticoagulation, pregnancy, prior reconstruction, and local expertise. A patient with severe sepsis may need the fastest reliable route. Definitive stone treatment follows after stabilization.

Residual Fragments and Follow-Up

A procedure is not complete merely because the patient wakes up and feels better. Residual fragments can remain after SWL, ureteroscopy, or PCNL. Some remain asymptomatic; others grow, migrate, or trigger recurrent infection. Follow-up imaging should be selected to answer the clinical question while minimizing unnecessary radiation.

Ask whether the operation achieved complete clearance, clinically insignificant residual fragments, or a planned staged result. Ask when stents or tubes will be removed and what imaging will confirm the final status. A forgotten device or unmonitored residual burden can convert a successful procedure into a preventable complication.

A Practical Comparison

Observation — strongest use case: stable, potentially passable ureteral stone. Primary advantage: avoids anesthesia and instrumentation. Main tradeoff: requires time, monitoring, and uncertainty tolerance.

Medical expulsive therapy — strongest use case: selected ureteral stones. Primary advantage: may improve passage in appropriate patients. Main tradeoff: benefit varies; side effects and follow-up still matter.

SWL — strongest use case: selected renal or ureteral stones with favorable features. Primary advantage: no ureteroscope required. Main tradeoff: fragmentation may be incomplete; repeat treatment may be needed.

Ureteroscopy — strongest use case: many ureteral and renal stones. Primary advantage: direct treatment and high clearance. Main tradeoff: anesthesia, possible stent, procedural risks.

PCNL or mini-PCNL — strongest use case: large or complex renal stone burden. Primary advantage: efficient removal and strong clearance. Main tradeoff: more invasive access and recovery.

Stent or nephrostomy — strongest use case: urgent decompression. Primary advantage: rapidly restores drainage. Main tradeoff: temporary device burden; stone remains for later treatment.

The best decision is shared, specific, and explicit about tradeoffs. A good surgeon should be able to explain not only why a procedure can work, but why it is preferred over the alternatives for that particular stone.